4.5 Letter

Target 5000: a standardized all-Ireland pathway for the diagnosis and management of inherited retinal degenerations

Journal

ORPHANET JOURNAL OF RARE DISEASES
Volume 16, Issue 1, Pages -

Publisher

BMC
DOI: 10.1186/s13023-021-01841-1

Keywords

Inherited retinal degenerations; Retinal dystrophy; Ocular genetics; Genetic diagnosis; Clinical diagnostic algorithm; Public and patient involvement

Funding

  1. Health Research Board Ireland
  2. Science Foundation Ireland
  3. Irish Research Council
  4. Health Research Charities Ireland/Fighting Blindness Ireland

Ask authors/readers for more resources

Target 5000 is an efficient and effective service for diagnosing and managing inherited retinal degenerations, providing personalized care plans for patients through genetic sequencing and collaboration with multidisciplinary teams. This service not only offers diagnosis, but also discovers novel genes and variants implicated in IRD, serving as a model for the development of similar programs in other countries.
Introduction: Inherited retinal degenerations (IRD) are rare genetic disorders with > 300 known genetic loci, manifesting variably progressive visual dysfunction. IRDs were historically underserved due to lack of effective interventions. Many novel therapies will require accurate diagnosis (phenotype and genotype), thus an efficient and effective pathway for assessment and management is required. Methods: Using surveys of existing practice patterns and advice from international experts, an all-Ireland IRD service (Target 5000) was designed. Detailed phenotyping was followed by next generation genetic sequencing in both a research and accredited laboratory. Unresolved pedigrees underwent further studies (whole gene/whole exome/whole genome sequencing). Novel variants were interrogated for pathogenicity (cascade screening, in silico analysis, functional studies). A multidisciplinary team (MDT; ophthalmologists, physicians, geneticists, genetic counsellors) reconciled phenotype with genotype. A bespoke care plan was created for each patient comprising supports, existing interventions, and novel therapies/clinical trials. Results and discussion: Prior to Target 5000, a significant cohort of patients were not engaged with healthcare/support services due to lack of effective interventions. Pathogenic or likely pathogenic variants in IRD-associated genes were detected in 62.3%, with 11.6% having variants of unknown significance. The genotyping arm of Target 5000 allowed a 42.73% cost saving over independent testing, plus the value of MDT expertise/processing. Partial funding has transferred from charitable sources to government resources. Conclusion: Target 5000 demonstrates efficacious and efficient clinical/genetic diagnosis, while discovering novel IRD-implicated genes/variants and investigating mechanisms of disease and avenues of intervention. This model could be used to develop similar IRD programmes in small/medium-sized nations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available